Comparing surgery versus radiation and chemotherapy for muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares three standard treatments for muscle-invasive bladder cancer: bladder removal surgery, radiation combined with chemotherapy, or both. It aims to find which approach works best while preserving quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 80 years old.
- Your bladder cancer must be a type called urothelial carcinoma that has spread into the muscle layer of the bladder (stages T2, T3, or T4a).
- You must be considered healthy enough to receive chemotherapy with a drug called cisplatin before your main treatment.
- You must have normal bladder function and be able to undergo a procedure to remove the bladder tumor (called TURBT) before treatment starts.
- You must not have cancer that has spread to distant organs or other major health problems that would make treatment unsafe.
- You must agree to use effective birth control during treatment and for 6 months after stopping it, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of bladder-sparing treatments for muscle-invasive bladder cancer, including surgery, chemotherapy, immunotherapy, and radiation, followed by maintenance immunotherapy. The goal is to see if this approach can control cancer while preserving the bladder, compared to a watch-and-wait approach.
This study looks at how chemotherapy given before bladder removal surgery changes the immune environment around the tumor. The goal is to see if these changes can help predict how well the treatment works, which could lead to better personalized care.
This study compares two ways to check if bladder cancer has grown into the muscle layer: an MRI scan (mpMRI) versus a standard surgery called TURBT (where a small tool removes a sample of the tumor). The goal is to see if the MRI can be as accurate as the surgery, so future patients might avoid an extra procedure.
This trial tests giving chemotherapy before surgery to remove the bladder, to see if it can improve outcomes for patients with muscle-invasive bladder cancer. The treatment is personalized based on a lab test of your tumor cells, which may help make the therapy more effective.
This study looks at how well a standard chemotherapy given before surgery works for muscle-invasive bladder cancer. It aims to see if higher responses lead to better outcomes.
This study tests a medication called nimotuzumab (a type of targeted therapy) added to standard chemoradiation (chemotherapy plus radiation) to treat muscle-invasive bladder cancer without surgically removing the bladder. The goal is to control the cancer while preserving the bladder.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.